Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Trial ID or NCT#

NCT00104962

Status

not recruiting iconNOT RECRUITING

Purpose

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.

Official Title

Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome

Eligibility Criteria

Ages Eligible for Study: 1 Year to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Neyssa Marina
Gary Dahl

Contact us to find out if this trial is right for you.

Contact

LPCH New Patient Coordinator
6507251072